Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.37 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | APEX1 | P27695 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34691 | 0.95 | BBOX1 (0.50) | BBOX1MEN1KMT2AAPEX1ACHE | |
| SCHEMBL34764 | 0.93 | BBOX1 (0.54) | BBOX1MEN1KMT2AAPEX1ACHE | |
| SCHEMBL34231 | 0.91 | BBOX1 (0.54) | BBOX1MEN1KMT2AAPEX1ACHE | |
| Sulfuric Acid SCHEMBL27735173 | 0.89 | BBOX1 (0.56) | BBOX1MEN1KMT2AAPEX1ACHE | |
| SCHEMBL918430 | 0.88 | BBOX1 (0.58) | BBOX1MEN1KMT2AAPEX1ACHE | |
| SCHEMBL5605270 | 0.85 | DNM1 (0.60) | MEN1KMT2AAPEX1ACHENFKB1 | |
| SCHEMBL10817018 | 0.85 | DNM1 (0.60) | MEN1KMT2AAPEX1ACHENFKB1 | |
| Cetrimonium SCHEMBL10817299 | 0.85 | DNM1 (0.60) | MEN1KMT2AAPEX1ACHENFKB1 | |
| SCHEMBL11144693 | 0.85 | DNM1 (0.60) | MEN1KMT2AAPEX1ACHENFKB1 | |
| SCHEMBL1253212 | 0.85 | DNM1 (0.60) | MEN1KMT2AAPEX1ACHENFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473277-B1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION OR ACID-FUNCTIONALIZED IONIC LIQUID | UNIV DENMARK TECH DTU (DK) | 2019-07-03 | — | — | EP | disclosed |
| US-20170341067-A1 | Palladium Catalyst System Comprising Zwitterion And/Or Acid-Functionalyzed Ionic Liquid | UNIV DENMARK TECH DTU (DK) | 2017-11-30 | — | — | US | disclosed |
| EP-2473277-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALIZED IONIC LIQUID | Technical University of Denmark (DK) | 2012-07-11 | — | — | EP | disclosed |
| US-20110065950-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALYZED IONIC LIQUID | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2011-03-17 | — | — | US | disclosed |
| WO-2011026860-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALIZED IONIC LIQUID | TECHNICAL UNIVERISTY OF DENMARK (DK) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065950-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALYZED IONIC LIQUID | PDCD2L, PCCA, PDK2 | SLC6A4 3705/4885BBOX1 1023/4885MEN1 1283/4885 |
| US-20170341067-A1 | Palladium Catalyst System Comprising Zwitterion And/Or Acid-Functionalyzed Ionic Liquid | PDCD2L, PCCA, PDK2 | SLC6A4 3705/4885BBOX1 1023/4885MEN1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.